31 Dec 2021 07:00
Syncona Limited
Β
Directorate Change
Β
31 December 2021
Β
Syncona Ltd, a leading healthcare company focused on founding, building and funding global leaders in life science, notes that as previously announced, Nigel Keen and Nicholas Moss step down as Non-Executive Directors on 31 December 2021.
Β
Virginia Holmes will become Senior Independent Director and Gian Piero Reverberi will become Chair of the Remuneration Committee, in each case from 1 January 2022.
Β
[ENDS]
Β
Enquiries
Β
Syncona Ltd
Natalie Garland-CollinsΒ /Β Fergus Witt
Tel: +44 (0) 7714 916615
Β
FTI Consulting
Ben AtwellΒ /Β Tim Stamper
Tel: +44 (0) 20 3727 1000
Β
Company Secretary
Citco Fund Services (Guernsey) Limited
Company Secretary
Tel: +44 (0) 1481 758228
Β
About Syncona:
Syncona'sΒ purpose is to invest to extend and enhance human life. We do this by founding and building companies to deliver transformational treatments to patients in areas of high unmet need.
Β
Our strategy is to found, build and fund companies around exceptional science to create a diversified portfolio of 15-20 globally leading healthcare businesses for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.
Β
Follow the stocks